Avid Bioservices Inc (CDMO)

[cjgaddy]

1-18-18/2017 ASM: Roger Lias’ Slideshow & Attendee Reports
...Attendee Reports are after the Slides. I will update & re-post as more come in over the next few days.

1-18-2018: Avid Bioservices’ 2017 Annual Shareholder’s Mtg http://ir.avidbio.com/events.cfm
…10amPT at Avid’s Myford Facility, 14191 Myford Road, Tustin, CA 72780
Webcast https://edge.media-server.com/m6/p/ij9i8ypx
...PROXY/14A: https://tinyurl.com/y7qprpg9 VotingRecDate=11-27-17

CEO Roger Lias’ ASM Presentation Slides (1-18-18):




























ATTENDEE REPORTS (2017 ASM 1-18-18):

By: Hawkfan1 (Michael) 1-18-18 9:41pmET #322974
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137796412
Here are some of my notes taken at the ASM. They are very brief paraphrases, since I never took shorthand in school.
As usual, Brandon Cox was the first to take the microphone with a long list of questions, that at least this shareholder very much appreciated.
Q. You are burning $3-4mm/qtr, with no cash and no back log. How do you plan to raise capital?
A. Your estimate of our burn rate is in the right ball park. We do have $33mm in backlog, but that is quite conservative. Most companies recognize all of an order when it is placed, but traditionally, PPHM has only recognized backlog as work orders for that order are placed. But clearly, we need more capital. We must eliminate the 'going concern' clause. While it may not be ideal for a small biotech, it is probably something they can live with. But for a manufacturing company, it is a death knell. Customers need to know that you are going to be around for the long term.
Q. How dilutive will it be?
A. We don't know yet. We don't know how much we will need yet.
Q. Is anyone from the old management team working to help sell the R&D technology?
A. Yes, Shelly. And others are working as consultants.
Q. Most CDMO's are private companies. Are there any plans to take the company private?
A. Not currently. (He did mention, kind of jokingly, that it would be nice).
Q. Who are the major institutional investors?
A. Still Ronan, Tappan, and Eastern Capital.
Q. Will they be involved in the capital raise?
A. Hopefully.
Q. What is the cost of being a public company?
A. About $2-3mm/year.
Q. As a strictly mfg. company, do we really need 7 board members?
A. Right now, the experience that they all bring is extremely helpfull. Down the road, maybe not.
Q. How much cash do we currently have?
A. $27.7mm. (Not quite sure I got this right, but I think that $10mm was in customer deposits). [NOTE: the $27.7mm is a/o 10-31-17, the last 10-Q (Deposits were $13.1mm): https://tinyurl.com/ybycb2s6 ]
Q. Will Avid expand beyond the earthquake prone Tustin area?
A. It could be done relatively easily. Down the road, it will be evaluated.
Then Brandon relinquished the mike and North40k gave a long and impassioned commentary about various trials and people (such as Dr. Wolchok) that the company should contact about Bavituximab. He mentioned Wolchok's comment that his next trial "depends on the company".
Dr. Lias stated that Dr. Wolchok has not contacted the company. He mentioned that an associate of Dr. Wolchok had said that it will be 18 mos. before the next trial proceeds. (This was met with incredulity from several shareholders in attendance).
Dr. Lias stated that they have numerous discussions regarding CAR-T, but there was no interest. In some other discussions, they found our technology interesting, but then said "prove it in a trial".
N40k then asked if the recent Halozyme trial failure would affect Avid. It will not.
Brandon Cox then resumed his questioning. He asked a question regarding the IP patent clock, which I previously reported. For continuity, Dr. Lias's answer was that as patents start to expire, and a BP realizes that it will take about $70mm and 3-4 years to bring a product to market, a 5-year patent life is not that exciting to them.
Q. How much Bavi do we have in storage?
A. Enough for a couple of small trials, nothing big.
Q. Client #1 is Halozyme. We don't know the name of client #2, but are they gone for good?
A. No, but I don't expect them to be hugely successful. They will be years down the road.
Q. Question regarding the interest in the Exosome test kit.
A. Not much commercial interest.
Q. Are you trying to sell the IP in bits and pieces or as a package deal?
A. While a package deal would be ideal, not gonna happen.
Then Greg got up and asked about the process of sell the IP. Dr. Lias commented that there was not much interest. The previous board has talked to everyone - it is not a secret - just not much interest.
Then N40k asked the board to contact Precision for Medicine, which concluded the Q&A.
Again, this is very roughly paraphrased from my notes. Other members that were in attendance, please correct anything that I may have inadvertently gotten wrong.
As I decided to take the tour, I was not able to talk to the board members one on one after the meeting.
BY: HAWKFAN1 (MICHAEL)
... 1-18-18 7:54pmET #322954 (INITIAL POST)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137794640
Dr. Lias comment about the lack of interest in the IP by BP was in response to a question by Brandon Cox about the declining IP clock. His example was that if BP knows that it will take about $70M and 3-4 years of trials to get a drug to market, then a 5-year patent life is just not that exciting to them. This doesn't address the question of getting a patent extension, however. If this is true, then Dr. Lias needs to be made aware of it.
FU #323010:
Just a few more general impressions from the meeting today. Like the rest of you, I was very disappointed in the approach to marketing the IP. On the one hand, Dr. Lias said that there were on-going discussions that he could not talk about, but he continually down played any expectation that we would receive much value for it. It was almost like they have already given up and have a 'Hey, we tried, but nobody is interested' attitude. They certainly didn't spell out any detailed marketing plan.
On the CDMO front, they generally impressed me as qualified, and will probably do a fine job, but I almost choked when Lias said that Tracy Kinjersky "hit the ground running". Hopefully, she will not emulate Mary Boyd.
The tour of the Myford facility was as impressive as ever. The 2 new 2000L reactors are installed, tested and ready to go, but have not yet been used in production. Someone asked how many employees we have now and we were told about 200, of which 30 something (I don't remember the exact number) are in production. I asked, if only 30 something are in production, what do the others do? I was told quality control, testing, etc., which I would consider as part of production. This brought the number up to about 75. Unfortunately, we were interrupted, and I wasn't able to pursue this breakdown any further.
It seems reasonable to me that we can get to $200mm in sales, but it will be at least 2-3 years down the road. They already have space in the Myford building to build out a duplicate of the existing facility, except that I believe it will use all 2000L reactors. But this space is still raw warehouse space, and will take a minimum of a year to build. And they won't start building it until they have reached significant profits from the exiting facility. So it all hinges on how fast they can attract new clients.

By: Holotawoopas 1/18/18 4:49pmET #322902
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137790910
For those who have pinned their hopes on the value of the IP it is time to mourn your loss and move on as there was nothing concrete about any potential monetizing extrapolated at the ASM. N40 gave a valiant effort to plead the case of value of the IP but IMO it fell on deaf ears! The CEO said no BP interest has been received!
FU#322909:
The CEO stated that the biggest down fall to monetizing the IP has nothing to do with leverage but has everything to do with patent expiration!!!

By: Eb0783 1/18/18 1:45pmET #322864
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137783413
ASM votes: #1 all re-elected, #2 for 36.4mm, #3 for 15.2 v. against 3.6, #4 1 year
FU#322879:
Per Lias, there is no formal process, group, or investment bank in place to sell the IP.
FU#322934:
Lias said he wasn't a patent expert when made those comments about short patent life being an issue. It was obvious he wasn't aware that patents could be extended due to years lost in development. Some of us took that short patent life excuse with a grain of salt.

By: Aikifredicist 1-18-18 8:16pmET #322961
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137795041
I got up at the meeting and asked about Exosomes, but Lias just fudged on the answer. He doesn’t know what he has.

= = = = = = = = = = = = = = =RECALL:
1-8-17: EBD's Biotech Showcase 2018 (parallel w/JPM Conf.), SanFran https://ebdgroup.knect365.com/biotech-showcase
...1-2-18 PR: https://tinyurl.com/ydcc9agv
...3:30pmPT: CEO Roger Lias, Corporate Presentation
...1-8-18 Lias BioShowcase’18 Presentation PDF (24 slides): https://tinyurl.com/ya6tgxxa

FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/ycb3fpfm
12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8

12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."